
Novo Nordisk's Wegovy receives FDA approval for reducing cardiovascular risks in adults with overweight or obesity and established cardiovascular disease. The approval is based on the SELECT trial, showing a 20% risk reduction in major cardiovascular events compared to placebo. Additional data demonstrate reduced risks of cardiovascular death and overall mortality. Wegovy is now indicated for long-term weight management and cardiovascular risk reduction. Novo Nordisk also seeks label expansion in the EU. Obesity, a chronic disease, necessitates sustained management due to its numerous health complications.
Like
Save
Share